Doriano Fabbro PhD

Dr. Doriano Fabbro, Chief Scientific Officer, received his Ph.D. in cell biology and biochemistry at the University of Basel. Doriano Fabbro an experienced leader and drug discoverer who has worked in the pharmaceutical industry for over 20 years, following 10 years in academia. As Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Basel Site, He has overseen a significant part of NIBR’s global oncology drug discovery portfolio from target discovery to clinical development. While working in the Oncology Drug Discovery, He has initiated and supported the development of drugs like Glivec, Tasigna, Afinitor, Midostaurin, as well as PI3K inhibitors, and many other signal transduction inhibitors that are in Phase I/II/III or preclinical development.